We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Detects Return of Blood Cancer a Year Earlier

By LabMedica International staff writers
Posted on 19 Jun 2024

Multiple myeloma, also known as Kahler's disease, is a type of blood cancer originating in the bone marrow characterized by the uncontrolled proliferation of plasma cells, a specific type of white blood cell. More...

Remarkably, half of the patients initially respond to treatment to a degree where the disease becomes undetectable in their blood, but unfortunately, the disease almost invariably returns. Currently, to monitor for the return of the disease, the standard practice involves a bone marrow biopsy, an invasive procedure that is not feasible to perform frequently. This method's reliability can also vary since the disease may not be uniformly distributed across the bone marrow. Alternatively, a less sensitive blood test is available, but it only detects the disease's return when the cancer cell count is considerably elevated. Now, researchers have developed a new blood test that can detect the return of multiple myeloma a full year earlier than the current standard blood test.

This advanced blood test, developed by scientists at Radboud University Medical Center (Nijmegen, the Netherlands) in collaboration with Erasmus MC (Rotterdam, Netherlands), is a thousand times more sensitive than the currently used blood test. It works by measuring antibodies produced by plasma cells, which are crucial to immune defense. Normally, a variety of plasma cells produce antibodies to combat different pathogens, but in multiple myeloma, one plasma cell type multiplies excessively, producing numerous identical plasma cells and antibodies, which the new test targets. Initially, customizing the test for individual patients required 125 days, but researchers have now refined the process to accommodate any patient and simultaneously test 25 patients, reducing the development time to just five days.

Moreover, the team has developed new software that enhances the measurement process, enabling even faster detection of tumor cell signals. In a trial involving forty patients, this test proved capable of detecting increases in cancer cells a year earlier than the standard blood test. The procedure needs less than a drop of blood, making it minimally invasive. Researchers are also exploring the possibility of patients performing the blood collection at home via a simple finger prick, which would bypass the need for hospital visits for blood draws, further innovating patient care in this field.

“Patients whose disease is no longer measurable after treatment often live in uncertainty for years”, said Hans Jacobs, Medical Immunologist. “With the new blood test, you can monitor much better, providing clarity. When the current blood test shows the cancer's return, the number of cancer cells is already high, and a different therapy is initiated. With the new test, we see the increase in cancer cells much earlier. This may allow for quicker and better adaptation of therapy to the patient’s situation, but we don’t know that yet. We will investigate this.”

Related Links:
Radboud University Medical Center 
Erasmus MC 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Capillary Blood Collection Tube
IMPROMINI M3
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The patented biosensor measures enzymatic activity associated with inflammatory disease (Photo courtesy of Hawkeye Bio)

Non-Invasive and Radiation-Free Diagnostic Identifies Early-Stage Lung Cancer Across All Subtypes

Lung cancer remains the leading cause of cancer-related deaths, with nearly 125,000 deaths and 227,000 new cases estimated in the U.S. for 2025. Despite evidence showing that early detection significantly... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.